KR20030070601A - 내성 유도없이 완전 d₁도파민 수용체 촉진제의 투여를통한 도파민-관련된 기능이상의 치료 방법 - Google Patents
내성 유도없이 완전 d₁도파민 수용체 촉진제의 투여를통한 도파민-관련된 기능이상의 치료 방법 Download PDFInfo
- Publication number
- KR20030070601A KR20030070601A KR10-2003-7009268A KR20037009268A KR20030070601A KR 20030070601 A KR20030070601 A KR 20030070601A KR 20037009268 A KR20037009268 A KR 20037009268A KR 20030070601 A KR20030070601 A KR 20030070601A
- Authority
- KR
- South Korea
- Prior art keywords
- promoter
- dopamine
- administration
- hours
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26188901P | 2001-01-16 | 2001-01-16 | |
US60/261,889 | 2001-01-16 | ||
PCT/US2002/001058 WO2002056875A2 (en) | 2001-01-16 | 2002-01-16 | Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20030070601A true KR20030070601A (ko) | 2003-08-30 |
Family
ID=22995315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-7009268A KR20030070601A (ko) | 2001-01-16 | 2002-01-16 | 내성 유도없이 완전 d₁도파민 수용체 촉진제의 투여를통한 도파민-관련된 기능이상의 치료 방법 |
Country Status (10)
Country | Link |
---|---|
US (2) | US6916823B2 (no) |
EP (1) | EP1351690A2 (no) |
JP (1) | JP2005504717A (no) |
KR (1) | KR20030070601A (no) |
CN (1) | CN1499968A (no) |
BR (1) | BR0206402A (no) |
CA (1) | CA2434736A1 (no) |
MX (1) | MXPA03006265A (no) |
NO (1) | NO20033192L (no) |
WO (1) | WO2002056875A2 (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
DE10066158B4 (de) * | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
EP1644004A4 (en) | 2003-06-20 | 2010-10-06 | Ronald Aung-Din | LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS |
US20050171139A1 (en) * | 2003-10-07 | 2005-08-04 | Hammer Ronald P.Jr. | Treating psychotic symptoms |
WO2005062894A2 (en) * | 2003-12-23 | 2005-07-14 | Darpharma, Inc. | Co-administration of dopamine-receptor binding compounds |
US20070254906A1 (en) * | 2004-07-21 | 2007-11-01 | Darpharma, Inc. | Method of Administration of Dopamine Receptor Agonists |
US20100150839A1 (en) * | 2005-02-04 | 2010-06-17 | Massachusetts Institute Of Technology | Compositions and Methods for Modulating Cognitive Function |
NZ570606A (en) * | 2006-02-21 | 2011-11-25 | Purdue Research Foundation | Trans-fused chromenoisoquinolines, synthesis and methods for use |
US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
US8592424B2 (en) * | 2008-06-30 | 2013-11-26 | Afgin Pharma Llc | Topical regional neuro-affective therapy |
WO2010017093A2 (en) * | 2008-08-05 | 2010-02-11 | Effipharma, Inc. | Dopamine receptor ligands with enhanced duration of action |
WO2010124005A1 (en) * | 2009-04-21 | 2010-10-28 | Purdue Research Foundation | Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor |
KR101850889B1 (ko) * | 2014-07-09 | 2018-04-20 | 삼성에스디아이 주식회사 | 화합물, 이를 포함하는 유기 광전자 소자 및 표시장치 |
US10716766B2 (en) | 2015-03-02 | 2020-07-21 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoids |
US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
CN107308135A (zh) * | 2017-06-26 | 2017-11-03 | 上海华迪机械有限公司 | 水凝胶贴剂制作工艺 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744476A (en) * | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
CA2227585A1 (en) * | 1995-08-18 | 1997-02-27 | Purdue Research Foundation | Novel fused isoquinolines as dopamine receptor ligands |
US6733797B1 (en) * | 2000-11-15 | 2004-05-11 | William K. Summers | Neuroceutical for improving memory and cognitive abilities |
-
2002
- 2002-01-16 MX MXPA03006265A patent/MXPA03006265A/es not_active Application Discontinuation
- 2002-01-16 KR KR10-2003-7009268A patent/KR20030070601A/ko not_active Application Discontinuation
- 2002-01-16 BR BR0206402-2A patent/BR0206402A/pt unknown
- 2002-01-16 WO PCT/US2002/001058 patent/WO2002056875A2/en not_active Application Discontinuation
- 2002-01-16 EP EP02707484A patent/EP1351690A2/en not_active Withdrawn
- 2002-01-16 CA CA002434736A patent/CA2434736A1/en not_active Abandoned
- 2002-01-16 JP JP2002557383A patent/JP2005504717A/ja active Pending
- 2002-01-16 US US10/050,289 patent/US6916823B2/en not_active Expired - Fee Related
- 2002-01-16 CN CNA028037391A patent/CN1499968A/zh active Pending
-
2003
- 2003-07-14 NO NO20033192A patent/NO20033192L/no not_active Application Discontinuation
-
2005
- 2005-06-13 US US11/151,145 patent/US20050232870A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20033192D0 (no) | 2003-07-14 |
WO2002056875A3 (en) | 2003-04-24 |
US20020132827A1 (en) | 2002-09-19 |
NO20033192L (no) | 2003-07-14 |
US20050232870A1 (en) | 2005-10-20 |
BR0206402A (pt) | 2006-01-17 |
WO2002056875A2 (en) | 2002-07-25 |
EP1351690A2 (en) | 2003-10-15 |
JP2005504717A (ja) | 2005-02-17 |
CN1499968A (zh) | 2004-05-26 |
US6916823B2 (en) | 2005-07-12 |
CA2434736A1 (en) | 2002-07-25 |
MXPA03006265A (es) | 2004-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050232870A1 (en) | Method of treatment of dopamine-related dysfunction | |
EP1634498B1 (en) | Exo-S-mecamylamine formulation | |
RU2515615C2 (ru) | Модуляторы нмда-рецептора и их применения | |
WO2008070149A2 (en) | Prodrugs and methods of making and using the same | |
CA2781436C (en) | Arachidonic acid analogs and methods for analgesic treatment using same | |
CA2380524A1 (en) | Compositions and methods for treating opiate intolerance | |
US5420134A (en) | Substituted hexahydrobenzo[A]phenanthridines | |
Austin et al. | Novel 1, 2, 3, 4-tetrahydroisoquinolines with high affinity and selectivity for the dopamine D3 receptor | |
AU777522B2 (en) | Chromeno(4,3,2-de)isoquinolines as potent dopamine receptor ligands | |
AU2002241889A1 (en) | Method of treatment of dopamine-related dysfunction through administration of a full D1 dopamine receptor agonist and with no induction of tolerance | |
JPS61501562A (ja) | 中枢作用アミン類の脳特異性類似化合物 | |
JP2001199884A (ja) | 鎮痛作用剤 | |
CA2135926C (en) | Substituted hexahydrobenzo[a]phenanthridines | |
WO2024055106A1 (en) | Amino acid and carbohydrate psilocin derivatives | |
GORDON et al. | REPORTS IN MEDICINAL CHEMISTRY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |